Burns J W & Co. Inc. NY Has $2.93 Million Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Burns J W & Co. Inc. NY boosted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.7% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 7,329 shares of the medical equipment provider’s stock after purchasing an additional 330 shares during the period. Burns J W & Co. Inc. NY’s holdings in Intuitive Surgical were worth $2,925,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of ISRG. Provence Wealth Management Group acquired a new stake in Intuitive Surgical in the 4th quarter worth $276,000. Portside Wealth Group LLC lifted its position in Intuitive Surgical by 8.2% in the fourth quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock worth $275,000 after purchasing an additional 62 shares during the period. Sequoia Financial Advisors LLC increased its holdings in Intuitive Surgical by 58.0% in the 4th quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after buying an additional 3,054 shares during the period. Public Employees Retirement System of Ohio lifted its holdings in shares of Intuitive Surgical by 5.4% during the 4th quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock worth $64,531,000 after acquiring an additional 9,869 shares during the period. Finally, HCR Wealth Advisors increased its stake in Intuitive Surgical by 26.3% in the fourth quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock valued at $352,000 after acquiring an additional 217 shares during the period. 83.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Piper Sandler upped their price objective on Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research note on Friday, April 19th. Jefferies Financial Group upped their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research note on Friday, April 19th. Stifel Nicolaus lifted their target price on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Citigroup raised their price target on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Finally, Robert W. Baird decreased their target price on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a report on Friday, April 19th. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average target price of $403.67.

Intuitive Surgical Stock Down 0.1 %

Shares of ISRG traded down $0.26 on Friday, hitting $444.85. The company’s stock had a trading volume of 3,106,192 shares, compared to its average volume of 1,372,778. The firm’s fifty day moving average price is $403.83 and its 200-day moving average price is $382.69. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $447.11. The firm has a market capitalization of $157.79 billion, a price-to-earnings ratio of 80.30, a P/E/G ratio of 5.75 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.00 earnings per share. As a group, equities analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the sale, the director now owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Craig H. Barratt sold 1,400 shares of the stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $421.06, for a total transaction of $589,484.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the transaction, the director now directly owns 25,319 shares in the company, valued at approximately $9,385,753.30. The disclosure for this sale can be found here. Insiders have sold a total of 17,956 shares of company stock worth $6,927,011 over the last three months. Corporate insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.